TY - GEN AU - Anna Maria Azzini AU - Romolo Marco Dorizzi AU - Piersandro Sette AU - Marta Vecchi AU - Ilaria Coledan AU - Elda Righi AU - Evelina Tacconelli TI - A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine. PY - 2020/// CY - [Place of publication not identified] PB - AME Publications KW - Antibiotic Therapy KW - Procalcitonin (Pct) KW - Evidence Based Laboratory Medicine (Eblm) KW - B. Sc. Medical Laboratory Science KW - UMUN open access collection KW - clinical chemistry KW - Review articles N1 - Publication type: Review article; Linked open-access copy: published version; Open access; no subscription required for the linked open-access version N2 - Biomarkers to guide antibiotic treatment decisions have been proposed as an effective way to enhancing a more appropriate use of antibiotics. As a biomarker, procalcitonin (PCT) has been found to have good specificity to distinguish bacterial from non-bacterial inflammations. Decisions regarding antibiotic use in an individual patient are complex and should be based on the pre-test probability for bacterial infection, the severity of presentation and the results of PCT serum concentration. In the context of a high pre-test probability for bacterial infections and/or a high-risk patient with sepsis, monitoring of PCT over time helps to track the resolution of infection and decisions regarding early stop of antibiotic treatment. As outlined by the Evidence Based Laboratory Medicine (EBLM), not only the pre-test probability but also the positive likelihood ratio influence the performance of a test do be really diagnostic. This aspect should be taken into account in the interpretation of the results of clinical trials evaluating the performance of PCT in guiding antibiotic therapy UR - https://europepmc.org/articles/PMC7290560 ER -